Calidi Biotherapeutics Files 8-K: Material Agreement
Ticker: CLDWW · Form: 8-K · Filed: Oct 11, 2024 · CIK: 1855485
| Field | Detail |
|---|---|
| Company | Calidi Biotherapeutics, Inc. (CLDWW) |
| Form Type | 8-K |
| Filed Date | Oct 11, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $5,100,000, $50,000, $7,500 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, filing, corporate-update
Related Tickers: CLDI
TL;DR
Calidi Biotherapeutics (CLDI) filed an 8-K on Oct 11, 2024, for a material definitive agreement. Details to follow.
AI Summary
On October 11, 2024, Calidi Biotherapeutics, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes financial statements and exhibits. The company, formerly known as First Light Acquisition Group, Inc., is incorporated in Delaware and headquartered in San Diego, California.
Why It Matters
This filing indicates a significant new agreement for Calidi Biotherapeutics, which could impact its business operations and financial standing. Investors should review the details of this material definitive agreement.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, and the specifics of this agreement are not yet detailed in the provided summary.
Key Numbers
- 001-40789 — SEC File Number (Identifies the company's filing with the SEC)
- 86-2967193 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Calidi Biotherapeutics, Inc. (company) — Registrant
- First Light Acquisition Group, Inc. (company) — Former company name
- October 11, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- San Diego, CA (location) — Business address city and state
FAQ
What is the nature of the material definitive agreement filed by Calidi Biotherapeutics?
The provided text states that an 8-K was filed for 'Entry into a Material Definitive Agreement' but does not specify the details of the agreement itself.
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated October 11, 2024.
What was Calidi Biotherapeutics' former company name?
Calidi Biotherapeutics, Inc. was formerly known as First Light Acquisition Group, Inc.
In which state is Calidi Biotherapeutics incorporated?
Calidi Biotherapeutics, Inc. is incorporated in Delaware.
What is the business address of Calidi Biotherapeutics?
The business address is 4475 Executive Drive, Suite 200, San Diego, CA 92121.
Filing Stats: 1,089 words · 4 min read · ~4 pages · Grade level 12.3 · Accepted 2024-10-11 17:05:23
Key Financial Figures
- $0.0001 — ch Registered Common stock, par value $0.0001 per share CLDI NYSE American LLC
- $5,100,000 — ng an aggregate offering price of up to $5,100,000. On October 11, 2024, the Company fil
- $50,000 — its counsel, in an amount not to exceed $50,000, in addition to certain ongoing disburs
- $7,500 — isbursements of its legal counsel up to $7,500 in connection with diligence bring down
Filing Documents
- form8-k.htm (8-K) — 51KB
- ex5-1.htm (EX-5.1) — 11KB
- form8-k_001.jpg (GRAPHIC) — 5KB
- ex10-1.htm (EX-10.1) — 261KB
- 0001493152-24-040953.txt ( ) — 611KB
- cldi-20241011.xsd (EX-101.SCH) — 4KB
- cldi-20241011_def.xml (EX-101.DEF) — 29KB
- cldi-20241011_lab.xml (EX-101.LAB) — 36KB
- cldi-20241011_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CALIDI BIOTHERAPEUTICS, INC. Dated: October 11, 2024 By: /s/ Andrew Jackson Name: Andrew Jackson Title: Chief Financial Officer